Fig. 6. CD47 monoclonal antibody (mAb)-treated mice show increased ferumoxytol uptake by tumor-associated macrophages (TAMs) and reduced tumor burden.

a Immunofluorescent confocal images of fluorescein isothiocyanate (FITC)-loaded ferumoxytol nanoparticles in F4/80⁺TAMs in MNNG/HOS tumors treated with IgG or CD47 mAb therapy (scale bar 10 μm). b Corresponding quantitative signal intensity of iron-FITC per macrophage in control and CD47 mAb-treated tumors. c Bioluminescent in vivo images (BLI) of MNNG/HOS tumors in mice treated with control IgG or CD47 mAbs. d Bioluminescent signal, quantified as total flux, of control or CD47 mAb-treated tumors on days 0, 5, and 10 of treatment. All results are represented as mean ± SD from six tumors per experimental group, p value as indicated, exact two-sided Wilcoxon rank-sum tests